肺動脈性肺高血圧症(PAH)の疫学的予測(~2024)

◆英語タイトル:EpiCast Report: Pulmonary Arterial Hypertension - Epidemiology Forecast to 2024
◆商品コード:GDHCER114-15
◆発行会社(調査会社):GlobalData
◆発行日:2016年1月1日
◆ページ数:72
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD3,995 ⇒換算¥407,490見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD7,990 ⇒換算¥814,980見積依頼/購入/質問フォーム
Enterprisewide License(複数国内共有可)USD11,985 ⇒換算¥1,222,470見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※レポート購入後、該当レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。



当調査レポートでは、肺動脈性肺高血圧症(PAH)の疫学的市場予測について調査・分析し、以下の構成でお届けいたします。

・イントロダクション
・肺動脈性肺高血圧症(PAH)の概要
・リスク要因及び併存症
・主要地域の動向
・疫学的予測方法
・肺動脈性肺高血圧症(PAH)の疫学的予測結果(有病率など)
・考察(結論、分析の限界・強み)
【レポートの概要】

EpiCast Report: Pulmonary Arterial Hypertension – Epidemiology Forecast to 2024

Summary

Pulmonary Arterial Hypertension (PAH) is a rare and severe condition characterized by vascular proliferation and remodeling of the small pulmonary arteries. This results in progressively increasing pulmonary vascular resistance, leading to an increase in pulmonary arterial pressure. The disease typically results in right-sided heart failure and premature death. PAH can be idiopathic, heritable, or associated with different conditions such as connective tissue disease (CTD), congenital heart disease (CHD), human immunodeficiency virus (HIV) infection, and exposure to toxins or drugs. PAH occurs twice as frequently in women as in men.

GlobalData epidemiologists forecast an increase in the diagnosed incident cases of PAH in the 7MM, from 1,769 diagnosed incident cases in 2014 to 1,838 diagnosed incident cases in 2024, with an Annual Growth Rate (AGR) of 0.39% during the forecast period. In 2024, the US will have the highest number of diagnosed incident cases of PAH in the 7MM, with 677 diagnosed incident cases, whereas the UK will have the lowest number of diagnosed incident cases of PAH, with 74 diagnosed incident cases. Similarly, the diagnosed prevalent cases of PAH in the 7MM are expected to increase from 9,926 diagnosed prevalent cases in 2014 to 10,285 diagnosed prevalent cases in 2024, with an AGR of 0.36% during the forecast period. In 2024, the US will have the highest number of diagnosed prevalent cases of PAH in the 7MM, with 4,325 diagnosed prevalent cases, whereas the UK will have the lowest number of diagnosed prevalent cases of PAH, with 443 diagnosed prevalent cases.

GlobalData’s epidemiological forecast for the diagnosed incident and the diagnosed prevalent cases of PAH in the 7MM is supported by age- and sex-specific data. The forecast methodology was kept consistent across the 7MM to allow for a meaningful comparison of the projected diagnosed incident cases and diagnosed prevalent cases of PAH across the markets. Additionally, GlobalData epidemiologists provided the diagnosed prevalent cases of PAH in each of the 7MM, segmented by the NYHA functional class I-IV, which is an important factor for predicting the prognosis, as well as the need for various clinical and treatment modalities specific to the functional classes, for PAH. GlobalData epidemiologists also provide an additional forecast for the diagnosed incident and diagnosed prevalent cases of PAH, adjusted for the underestimation of registry based forecast. These two different types of forecast strengthen the analysis, and present a comparative assessment of the extent of underestimation when using registry based data, which can be evaluated to provide better insights on the burden of the condition.

Scope

- The Pulmonary Arterial Hypertension (PAH) EpiCast Report provides an overview of the risk factors, comorbidities, and global trends for RSV infection in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast of the diagnosed incident cases and diagnosed prevalent cases of PAH, segmented by sex, and age (in 10-year increments beginning at 0 years and ending at =85 years in these markets.
- The PAH epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 10MM.

Reasons to buy

The PAH EpiCast report will allow you to –
- Develop business strategies by understanding the trends shaping and driving the global PAH market.
- Quantify patient populations in the global PAH market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for PAH therapeutics in each of the markets covered.

【レポートの目次】

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 6
1.2 List of Figures 7
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10
2.3 Upcoming Reports 11
3 Epidemiology 12
3.1 Disease Background 12
3.2 Risk Factors and Comorbidities 14
3.3 Global Trends 15
3.3.1 Incidence and Prevalence 15
3.4 Forecast Methodology 17
3.4.1 Sources Used 20
3.4.2 Sources Not Used 25
3.4.3 Forecast Assumptions and Methods 26
3.5 Epidemiological Forecast for PAH (2014-2024) 32
3.5.1 Epidemiological Forecast for PAH – Based on Registry Data 33
3.5.2 Epidemiological Forecast for PAH – Adjusted for Underestimation 47
3.6 Discussion 60
3.6.1 Epidemiological Forecast Insight 60
3.6.2 Limitations of the Analysis 61
3.6.3 Strengths of the Analysis 62
4 Appendix 64
4.1 Bibliography 64
4.2 About the Authors 67
4.2.1 Epidemiologists 67
4.2.2 Reviewers 67
4.2.3 Global Director of Therapy Analysis and Epidemiology 68
4.2.4 Global Head of Healthcare 69
4.3 About GlobalData 70
4.4 About EpiCast 70
4.5 Disclaimer 71

1.1 List of Tables
Table 1: WHO Guidelines, Modified New York Heart Association Functional Classes I-IV 13
Table 2: Risk Factors and Comorbidities for PAH 14
Table 3: 7MM, Global Trends for the Diagnosed Incidence of PAH 16
Table 4: 7MM, Global Trends for the Diagnosed Prevalence of PAH 17
Table 5: 7MM Sources of Epidemiological Data Used for the Forecast for PAH Diagnosed Incident Cases (Based on Registry Data) 18
Table 6: 7MM Sources of Epidemiological Data Used for the Forecast for PAH Diagnosed Prevalent Cases (Based on Registry Data) 19
Table 7: 7MM Sources of Epidemiological Data Used for the Classification of Diagnosed Prevalent Cases* According to the NYHA Functional Classes I-IV 20
Table 8: 7MM, Diagnosed Incident Cases of PAH, Both Sexes, All Ages, N, 2014-2024 (Based on Registry Data) 33
Table 9: 7MM, Age-Specific Diagnosed Incident Cases of PAH, Both Sexes, N (Row %), 2014 (Based on Registry Data) 35
Table 10: 7MM, Sex-Specific Diagnosed Incident Cases of PAH, All Ages, N (Row %), 2014 (Based on Registry Data) 37
Table 11: 7MM, Diagnosed Prevalent Cases of PAH, Both Sexes, All Ages, N, 2014-2024 (Based on Registry Data) 40
Table 12: 7MM Age-Specific Diagnosed Prevalent Cases of PAH, Both Sexes, N (Row %), 2014 (Based on Registry Data) 42
Table 13: 7MM, Sex-Specific Diagnosed Prevalent Cases of PAH, All Ages, N (Row %), 2014 (Based on Registry Data) 44
Table 14: 7MM, Diagnosed Incident Cases of PAH, Both Sexes, All Ages, N, 2014-2024 (Adjusted for Underestimation) 48
Table 15: 7MM, Age-Specific Diagnosed Incident Cases of PAH, Both Sexes, N (Row %), 2014 (Adjusted for Underestimation) 50
Table 16: 7MM, Sex-Specific Diagnosed Incident Cases of PAH, All Ages, N (Row %), 2014 (Adjusted for Underestimation) 52
Table 17: 7MM, Diagnosed Prevalent Cases of PAH, Both Sexes, All Ages, N, 2014-2024 (Adjusted for Underestimation) 54
Table 18: 7MM, Age-Specific Diagnosed Prevalent Cases of PAH, Both Sexes, N (Row %), 2014 (Adjusted for Underestimation) 56
Table 19: 7MM, Sex-Specific Diagnosed Prevalent Cases of PAH, All Ages, N (Row %), 2014 (Adjusted for Underestimation) 58

1.2 List of Figures
Figure 1: 7MM, Diagnosed Incident Cases of PAH, Both Sexes, All Ages, N, 2014-2024 (Based on Registry Data) 34
Figure 2: 7MM, Age-Specific Diagnosed Incident Cases of PAH, Both Sexes, N, 2014 (Based on Registry Data) 36
Figure 3: 7MM, Sex-Specific Diagnosed Incident Cases of PAH, All Ages, N, 2014 (Based on Registry Data) 38
Figure 4: 7MM, Age-Standardized Diagnosed Incidence of PAH (Cases per 100,000 Population), All Ages, by Sex, 2014 (Based on Registry Data) 39
Figure 5: 7MM, Diagnosed Prevalent Cases of PAH, Both Sexes, All Ages, N, 2014-2024 (Based on Registry Data) 40
Figure 6: 7MM Age-Specific Diagnosed Prevalent Cases of PAH, Both Sexes, N, 2014 (Based on Registry Data) 43
Figure 7: 7MM, Sex-Specific Diagnosed Prevalent Cases of PAH, All Ages, N, 2014 (Based on Registry Data) 45
Figure 8: 7MM, Age-Standardized Diagnosed Prevalence of PAH (%), All Ages, by Sex, 2014 (Based on Registry Data) 46
Figure 9: 7MM, Diagnosed Prevalent Cases of PAH Categorized into NYHA Functional Classes (N), All Ages, 2014 (Based on Registry Data) 47
Figure 10: 7MM, Diagnosed Incident Cases of PAH, Both Sexes, All Ages, N, 2014-2024 (Adjusted for Underestimation) 48
Figure 11: 7MM, Age-Specific Diagnosed Incident Cases of PAH, Both Sexes, N, 2014 (Adjusted for Underestimation) 51
Figure 12: 7MM, Sex-Specific Diagnosed Incident Cases of PAH, All Ages, N, 2014 (Adjusted for Underestimation) 53
Figure 13: 7MM, Diagnosed Prevalent Cases of PAH, Both Sexes, All Ages, N, 2014-2024 (Adjusted for Underestimation) 54
Figure 14: 7MM, Age-Specific Diagnosed Prevalent Cases of PAH, Both Sexes, N, 2014 (Adjusted for Underestimation) 57
Figure 15: 7MM, Sex-Specific Diagnosed Prevalent Cases of PAH, All Ages, N, 2014 (Adjusted for Underestimation) 59
Figure 16: 7MM, Diagnosed Prevalent Cases of PAH Categorized into NYHA Functional Classes (N), All Ages, 2014 (Adjusted for Underestimation) 60

【レポートのキーワード】

肺動脈性肺高血圧症(PAH)

【免責事項】
※当レポート上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当レポートに記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当レポート上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチ(株)はその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチ(株)が翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

★調査レポート[肺動脈性肺高血圧症(PAH)の疫学的予測(~2024)]についてメールでお問い合わせはこちら


※世界の市場調査資料 総合販売サイトMarketReport.jpはH&Iグローバルリサーチ株式会社が運営しております。海外進出、グローバル事業戦略策定、新規事業機会の発掘、競合他社の動向把握などに必要な情報やインサイトをお客様にご提供しております。H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。
※当サイトでは2016年08月25日現在 202,314 件の調査レポートを取り扱っております。当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。

◆H&Iグローバルリサーチのお客様(例)◆